摘要:
The present invention provides a novel monoclonal antibody, mAb C1.7, and its antigenic receptor, p38, which is an NK cell and CD8.sup.+ T cell activating structure. Methods of using these compositions to identify and monitor the course of a disease, as well as for therapeutic purposes, are disclosed.
摘要:
Methods of inducing gamma interferon production and stimulating lymphocyte populations using Natural Killer Stimulatory Factor (NKSF) are disclosed.
摘要:
Improved vaccine compositions and methods of making the compositions are provided, which vaccines are characterized by an antigen from a pathogen and an effective adjuvanting amount of Interleukin-12 (IL-12). These IL-12 adjuvanted vaccines are capable of increasing the vaccinated host's cell mediated immune response to provide an increased and protective immune response to the pathogen. Also disclosed are methods for vaccinating hosts by administering a vaccine containing an antigen from a pathogenic microorganism and co-administering an adjuvanting amount of IL-12. Vaccines or therapeutic compositions directed against a cancer may also be adjuvanted with IL-12 according to this invention.
摘要:
A novel homogeneous human cytokine, Natural Killer Stimulatory Factor, having the ability to induce the production of gamma interferon in vitro in human peripheral blood lymphocytes, and a pharmaceutical preparation containing it.